The 10 Companies Booming in Healthcare Sector

More documents

Recommendations

Info

OncoSnap® is a pioneering tumor tissue profiling test which screens for clinically relevant somatic mutations of 130 genes in solid tumor tissues by using NGS technologies, and offers FDA-approved therapies undergoing clinical trials. Able to detect single nucleotide variations (SNVs), insertions and deletions (indels), selected fusions and copy number alterations OncoSnap BRCATM is a pioneering NGS-based tumor tissue profiling test which screens for somatic mutations of BRCA1 and BRCA2 genes in solid tumor tissues. This test is useful for assessing patients who are diagnosed with breast cancer, ovarian cancer and prostate cancer on whether they could be benefited from selected PARP inhibitor treatments. OncoSnap NonetTM screens for 9 genes in tumor tissue samples, intending to aid physicians to identify multi-genetic biomarkers for potential treatment options for primary diagnosed non-small-cell lung cancer patients. PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 to detect PD-L1 protein in FFPE tissue specimens using EnVision FLEX visualization system on Autostainer Link 48. It detects PD-L1 expression with a dynamic range of tumor-positive (TPS) 0-100% and combined positive score (CPS) 0-10+. Cancers include lung cancer, gastric cancer, urothelial cancer, cervical cancer, etc. EmbryoSafeTM screens all 24 chromosomes of IVF and ICSI embryos to detect pathogenic chromosome copy number changes, including aneuploidy, mosaicism, unbalanced translocations, and microduplications/microdeletions (> 10 Mb). 5. With respect to your distinctive products and services, how have you helped bring positive developments in the healthcare industry? Sanomics contributed to provide genomic tests to help doctors decide personalized cancer solutions for patients. We keep providing solutions to tackle with the pain points in current cancer management process. For example, Sanomics is the first local private company in Hong Kong to adopt liquid biopsy, a non-invasive cancer screening technology that spares patients from the painful tissue biopsy, a traditional procedure of collecting tissue samples from tumors. Another example is that tissue samples often run outs before answering all the clinical questions that guide treatment selection, therefore, TM by launching OncoSnap Nonet , this test can screen for 9 genes in tumor tissue samples to make best use of tissue. 6. Are there any social activities that your company organizes to uplift healthcare space? To raise the public awareness of adopting genomic test in cancer management, Sanomics organizes workshops and seminars for healthcare professionals and general public. We also co-operate with our strategic partners, such as 18 | June 2019 |
AstraZeneca and Bio-Rad to organize large scale symposium, to discuss about the latest development of genomic diagnostics and provide a platform for intellectual exchange in the healthcare industry. 7. Tell us some interesting things about your leader (CEO, CFO, COO or any other personality which you want to highlight in this issue). “Keep moving, keep thinking and keep solving”, this is the common value that we share in Sanomics. 8. Mention the notable awards and accreditations Sanomics has received so far. So far, Sanomics has won 19 awards. Some highlighted awards include: 2018 The Top 50 Innovative Biotechnology Enterprises in Guangdoug-Hong Kong-Macau Greater Bay Area by ZDVC Research Institute, KPMG & Guangdoug Medical Valley Innovative Business Gold Award 2018 by The Hong Kong and Shanghai Banking Corporation Limited and Hong Kong Economic Times Caring Company Award by The Hong Kong Council of Social Service 9. Can you share with us your upcoming projects? Big data will be our next step. Big Data is everywhere in our daily life, actually DNA big data can also be digitalized to assist scientists and doctors to analyze and make advances in cancer treatment. Currently, there is no existing DNA database of Asian cancer patients. To address the need for building Asian cancer patients’ big data, we initiate to establish a DNA Big Data Centre in Hetao district at Lok Ma Chau. By doing so, we aim to attract more genetic related start-ups to set up their offices in Great Bay Area, so as to create an ecosystem of biotechnology companies in Great Bay Area. The initial design of this DNA big database is by subscription base. The meta data of the database will be open for public access. However, to get full access, users must register and pay certain amount of subscription fee, as well as unveiling their data model to sustain the platform. The three main roles of the owner of this DNA Big Data Centre are - first, to provide basic legal support and protection to the DNA data supplying and demanding sides; second, to set up a rating scheme and payment scheme for DNA data transaction; and thirdly, to be the DNA big data manager. The idea of this Asian DNA big data base is like a combination of Asian DNA eBay and DNA cloud. We believe that more valuable studies and commercialized applications of DNA data will be generated once this Asian Big Data sharing platform has been launched. We foresee that ultimately this will enhance the overall life quality and improve the cancer solution for Asian. Fig.: Important Milestones in the Journey of Sanomics | June 2019 | 19
Page 1: 2019 Vol.6/ Issue-2 www.insightscar
Page 5 and 6: Editor’s Column
Page 7 and 8: CONTENTS 24 32 34 David Health Solu
Page 9: Editor-in-Chief Pooja M. Bansal Sen
Page 13 and 14: Cover Story NOVOTECH A Catalyst for
Page 15 and 16: ” We maintain and monitor the qua
Page 18 and 19: Interview with Insights Care Mr. Sy
Page 24 and 25: Tania Martin-Mercado Chief Technolo
Page 26 and 27: ‘‘ ‘‘ eadquarter in Helsink
Page 28 and 29: patients care for a variety of musc
Page 30 and 31: In-house Opinion Social Media Marke
Page 32: Healthcare industry is also affecte
Page 35 and 36: Eclectic Services Accutest provides
Page 37 and 38: across the US and outside the US, i
Page 39 and 40: Novel Discoveries Top Health Tech I
Page 41: ROBOTIC SURGERY Robotics has been a

The 10 Companies Booming in Healthcare Sector

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?